

**NRES Committee East of England -  
Cambridge South**

**Annual Report**

**01 April 2012 – 31 March 2013**

## Part 1 – Committee Membership and Training

<b>Name of REC:</b>	NRES Committee East of England - Cambridge South
<b>Type of Flag:</b>	IRB Registered Research Involving Children
<b>Chair:</b>	Dr Leslie Gelling
<b>Vice-Chair:</b>	Dr Frank Wells
<b>Alternate Vice-Chair:</b>	Dr Ian Dumbelton
<b>Co-ordinator:</b>	Miss Susan Davies 01.04.12 – 01.02.13 (Cambridge Office) Ms Trish Wheat 01.02.13 – 31.03.13
<b>PRSC Co-ordinator:</b>	Miss Susan Davies 01.04.12 – 01.02.13 (Cambridge Office)
<b>Assistant Co-ordinator:</b>	Miss April Saunders, Ms Har Hari Kaur, Ms Melanie Johnson (Cambridge Office) 01.04.12 – 01.02.13
<b>Committee Address:</b>	The Old Chapel Royal Standard Place Nottingham NG1 6FS
<b>Telephone:</b>	0115 8839308 (Direct Line)
<b>Fax:</b>	
<b>Email:</b>	nrescommittee.eastofengland-cambridgeeast@nhs.net

### **Chair's overview of the past year:**

This has been another busy year for Cambridge South REC. The Committee has maintained an experienced and committed membership, which takes pride in the quality of the ethical review provided to researchers and to the public. I have no concerns about how the Committee has conducted its reviews or how the Committee has been supported by NRES coordinators and other staff.

## NRES Committee East of England - Cambridge South Membership:

Name	Occupation	Expert or Lay	Dates	
			Appointed	Resigned
Mrs Martha Byrne	Clinical QA Manager	Lay Plus	01/04/2011	
Dr Katherine Catford	Specialist Registrar in Paediatrics	Expert	01/10/2011	
Dr Andrew Clark	Consultant in Paediatric Allergy	Expert	01/04/2011	20/08/2012
Dr Ian Dumbelton	Retired General Medical Practitioner	Expert	01/04/2011	
Dr Leslie Gelling	(Chair) Reader in Research Ethics	Expert	01/04/2011	
Mr Colin Green	Drugs & Therapeutics Pharmaceutical Advisor	Expert	01/04/2011	
Mrs Alison Hall	Project Manager	Lay	01/04/2011	
Mr Malcolm Lee	Retired Teacher	Lay Plus	01/04/2011	
Miss Angela Palmer	Retired Patent Litigator	Lay Plus	01/04/2011	
Mrs Nikki Phillimore	Antibiotic/infection management pharmacist	Expert	01/04/2011	
Miss Carol Smee	Regulatory Advisor	Lay	01/04/2011	
Mr Phil Tempest	Compliance Manager	Lay	01/04/2011	
Dr Frank Wells	(Vice-Chair) Retired Pharmaceutical Physician	Expert	01/04/2011	
Dr Kate Williams	Senior Research Associate	Lay	01/04/2011	
Miss Louise Wilmer	Pharmacist Team Manager - Cancer Services	Expert	01/04/2011	27/09/2012
Dr Rashid Zaman	Consultant Psychiatrist and Director of Bedfordshire Centre for Mental Health Research	Expert	01/04/2011	

### Deputy Members

Name	Occupation	Expert or Lay	Meeting date attended
Mrs Nikki Phillimore (deputy to Louise Wilmer to 27/09/2012)	Antibiotic/infection management pharmacist	Expert	26/04/2012 26/07/2012 23/08/2012
Miss Poonam Dhokia (deputy to Louise Wilmer from 08/10/2012)	Medicines Information Pharmacist	Expert	25/10/2012 24/01/2013 28/03/2013

## NRES Committee East of England - Cambridge South: Members' Declarations of

Name	Declaration of Interest	Date
Mr Malcolm Lee	None	10/04/2012
Dr Katherine Catford	None	22/06/2012
Dr Rashid Zaman	Member of South Asian Health Foundation (SAHF) a charity. Director BCMHR-CU (Bedfordshire Centre for Mental Health Research in association with University of Cambridge).Lead for NHS engagement and social care for MHRN (mental health research network).Member of Research Governance group for employing Trust (SEPT).	06/11/2012
Miss Poonam Dhokia	None.	06/11/2012
Mrs Nikki Phillimore	None.	14/11/2012
Mr Phil Tempest	PT is employed by Amgen Ltd as Compliance Senior Manager.PT holds shares in Amgen Ltd and GlaxoSmithKline Plc.	17/11/2012
Dr Kate Williams	None.	31/10/2012
Dr Frank Wells	None.	31/10/2012
Mr Colin Green	None.	31/10/2012
Dr Leslie Gelling	Director of Research, FHSCE, Anglia Ruskin University Reader in Research Ethics, FHSCE, Anglia Ruskin University Consultant, Clinfield	02/11/2012
Miss Angela Palmer	Angela spent all her working life (40+ years) at GSK or it's predecessor companies, firstly in Chemistry Research and then in Patents/Patent litigation. Angela receives a pension from GlaxoWellcome. She has not however had any association with the GSK facility at Addenbrookes .Angela holds GSK shares.	06/11/2012
Miss Carol Smee	Carol is employed by Wellcome Trust Sanger Institute as a Regulatory Advisor (full-time position).	09/11/2012
Dr Ian Dumbelton	None	28/12/2012
Mrs Martha Byrne	CQA Manager - Napp PharmaceuticalsGCP Committee Non-Executive Director of RQA (Research Quality Association) - to provide oversight and review of clinical trial guidance and regulations on behalf of Good Clinical Practice Members .EQAC (European QA Confederation) - Rapporteur for review of EMA legislation and other guidances on behalf of QA societies across Europe since 2011.Addenbrooke's Hospital NHS Foundation Trust Public Member since 2006.GCP Committee Chair of RQA (Non-Executive Director)RQA GCP Committee Member since 2003RQA Member since 1999	16/01/2013
Miss Louise Wilmer	Lead Pharmacist for Cancer services (including clinical trials) - Peterborough City Hospital -	27/09/2012

	Reviewing trials within the hospital cancer services. Line manager member of staff who sits on R&D committee and very occasionally may cover R&D committee meeting	
Mrs Alison Hall	Senior Policy Advisor employed by the Foundation for Genomics and Population health (PHG Foundation) charity no. 1118664, company no. 5823194	13/01/2013

#### Meetings for Full Ethical Review 01 April 2012 - 31 March 2013:

Month	Date	Number of Members Present at Meeting
April	26/04/2012	10
May	24/05/2012	9
June	28/06/2012	12
July	26/07/2012	7
August	23/08/2012	7
September	27/09/2012	10
October	25/10/2012	11
November	22/11/2012	12
January	24/01/2013	9
March	28/03/2013	7

10 full committee meetings were held during the reporting period.

#### Proportionate Review Sub Committee Meetings held during 01 April 2012 - 31 March 2013:

Month	Date	Number of Members Present at Meeting
May	10/05/2012	4
June	07/06/2012	4
September	06/09/2012	4
November	08/11/2012	4

4 proportionate review sub-committee meetings were held during the reporting period.

**Attendance of Members: 01 April 2012 – 31 March 2013:**

<b>Name</b>	<b>Number of Meetings Attended</b>
Miss Angela Palmer	9
Dr Kate Williams	9
Dr Leslie Gelling	8
Mr Phil Tempest	8
Miss Carol Smee	8
Dr Frank Wells	8
Mrs Alison Hall	7
Mr Colin Green	7
Mrs Martha Byrne	5
Dr Ian Dumbelton (break in service from 01/03/2013)	5
Dr Rashid Zaman	5
Mr Malcolm Lee (break of service from 01/01/2013)	4
Dr Andrew Clark (resigned 20/08/2012)	3
Miss Louise Wilmer (resigned 27/09/2012)	3
Dr Katherine Catford (break in service 01/04/2012 to 31/10/2012)	3
Mrs Nikki Phillimore (deputy member to 27/09/2012)	1
Miss Poonam Dhokia	3

**Number of inquorate meetings held: 0**

**Attendance of Members at proportionate review sub-committee meetings:  
01 April 2012 – 31 March 2013:**

<b>Name</b>	<b>Number of Meetings Attended</b>
Dr Leslie Gelling	4
Dr Frank Wells	2
Miss Carol Smee	2
Mr Phil Tempest	2
Mrs Alison Hall	2
Mr Colin Green	1
Mr Malcolm Lee	1
Dr Kate Williams	1
Miss Angela Palmer	1

**Training 01 April 2012 – 31 March 2013:**

<b>Name of Member</b>	<b>Date</b>	<b>Event(s) attended</b>
Dr Frank Wells	09/10/2012 - 09/10/2012	NRES Researcher Training Day, NRES
Dr Leslie Gelling	07/11/2012 - 07/11/2012	Members National Training Day, NRES
Mr Malcolm Lee	10/04/2012 - 10/04/2012	Equality & Diversity, NRES
Dr Leslie Gelling	05/12/2012 - 05/12/2012	Chairs National Training Day, NRES
Mrs Martha Byrne	08/06/2012 - 08/06/2012	Information Sheet and Consent Forms Version 3.1 April 2007 (and Sept 08)
Dr Kate Williams	29/10/2012 - 29/10/2012	Ethics & GCP Forum
Miss Carol Smee	21/09/2012 - 21/09/2012	Research Data and Confidentiality, MRC
Mr Colin Green	21/11/2012 - 21/11/2012	GCP Training
Dr Frank Wells	05/12/2012 - 05/12/2012	Chair's National Training Day, HRA
Dr Leslie Gelling	13/12/2012 - 13/12/2012	Cambs South Training Meeting - December 2012, Dr Leslie Gelling
Dr Katherine Catford	13/12/2012 - 13/12/2012	South Cambs Training Day, Dr Leslie Gelling
Miss Poonam Dhokia	13/12/2012 - 13/12/2012	Cambs South Training Day, Dr Leslie Gelling
Dr Ian Dumbelton	13/12/2012 - 13/12/2012	Cambs South Training Meeting, Dr Leslie Gelling
Mrs Alison Hall	13/12/2012 - 13/12/2012	Cambs South Training Meeting, Dr Leslie Gelling
Miss Angela Palmer	13/12/2012 - 13/12/2012	Cambs South Training Meeting, Dr Leslie Gelling
Mrs Nikki Phillimore	13/12/2012 - 13/12/2012	Cambs South Training Meeting, Dr Leslie Gelling
Miss Carol Smee	13/12/2012 - 13/12/2012	Cambs South Training Meeting, Dr Leslie Gelling
Mr Phil Tempest	13/12/2012 - 13/12/2012	Cambs South Training Meeting, Dr Leslie Gelling
Dr Frank Wells	13/12/2012 - 13/12/2012	Cambs South Training Meeting, Dr Leslie Gelling
Dr Kate Williams	13/12/2012 - 13/12/2012	Cambs South Training Meeting, Dr Leslie Gelling
Dr Rashid Zaman	13/12/2012 - 13/12/2012	Cambs South Training Meeting, Dr Leslie Gelling
Mrs Nikki Phillimore	16/01/2013 - 16/01/2013	Equality & Diversity, HRA
Dr Leslie Gelling		Equality & Diversity, Anglia Ruskin University

**Part 2: REC workload and activity during the reporting period.**

**Table 1: Applications assigned to a full committee meeting held within the reporting period:**

<b>Applications for full ethical review – Study Type</b>	<b>Number</b>	<b>%</b>
Clinical Trial of Investigational Medicinal Product	12	24.00
Phase 1	0	0.00
Gene Therapy	0	0.00
Research Tissue Bank	0	0.00
Research Database	0	0.00
Others	38	76.00
<b>Total Applications Reviewed</b>	<b>50</b>	<b>100</b>

**Table 2: Other REC activity during the reporting period:**

Number of applications made invalid by co-ordinator	2
Number of studies withdrawn prior to the meeting	3
Number of student applications reviewed	14
Number of paediatric applications reviewed	13
Number of device applications reviewed	0
Number of prisoner applications reviewed	0
Number of applications involving adults unable consent reviewed	0
Number of applications reviewed funded by the US DHHS	1

**Table 3: Decisions given at meetings held within the reporting period:**

<b>Decisions taken at meetings following review of applications</b>	<b>Number</b>	<b>%</b>
Favourable Opinion with Standard Conditions	0	0.00
Favourable Opinion with Additional Conditions	5	10.00
Unfavourable Opinion	4	8.00
Provisional Opinion	41	82.00
Invalid	0	0.00
No Opinion Pending Consultation with Referee	0	0.00
Provisional Opinion Pending Consultation with Referee	0	0.00
Not Requiring Review by NHS REC	0	0.00
<b>Total</b>	<b>50</b>	<b>100</b>
Number of studies sent back to full committee meeting for final opinion	0	

**Table 4: Summary of current status of applications reviewed during the reporting period:**

<b>Status of applications at date of generation of report</b>	<b>Number</b>	<b>%</b>
Further Information Favourable Opinion with Standard Conditions	34	68.00
Further Information Favourable Opinion with Additional Conditions	4	8.00
Further Information Unfavourable Opinion	0	0.00
Favourable Opinion with Standard Conditions	0	0.00
Favourable Opinion with Additional Conditions	5	10.00
Unfavourable Opinion	4	8.00
Provisional Opinion	3	6.00
Provisional Opinion Pending Consultation with Referee	0	0.00
Invalid	0	0.00
No Opinion Pending Consultation with Referee	0	0.00
Further Information response not complete	0	0.00
Not Requiring Review by NHS REC	0	0.00
No decision entered on RED	0	0.00
Number of studies withdrawn after the meeting	0	0.00
<b>Total</b>	<b>50</b>	<b>100</b>

**Table 5: Applications assigned to a proportionate review sub-committee within the reporting period:**

<b>Total Applications Reviewed</b>	<b>9</b>
------------------------------------	----------

**Table 6: Decisions given at proportionate review sub-committee meetings held within the reporting period:**

<b>Decisions taken at proportionate review sub-committee meetings</b>	<b>Number</b>	<b>%</b>
Favourable Opinion with Standard Conditions	3	33.33
Favourable Opinion with Additional Conditions	0	0.00
No Opinion transfer to full committee for review	1	11.11
Provisional Opinion	4	44.44
Unfavourable Opinion	1	11.11
<b>Total</b>	<b>9</b>	<b>100</b>

**Table 7: Other Management Information for the reporting period:**

<b>Average number of applications reviewed per full meeting</b>	5.00
<b>Number of applications for full ethical review over 60 days</b>	1
<b>Number of applications over 60 days as a % of total</b>	2.00%
<b>Number of days taken to final decision - average</b>	43
<b>Number of days taken to final decision - mode</b>	26
<b>Number of SSAs (non-Phase 1) reviewed</b>	7
<b>Number of applications for SSA review over 25 days</b>	2
<b>Number of applications for SSA review over 25 days as % of all non-Phase 1 (SSAs)</b>	28.6%
<b>Number of SSAs (Phase 1) reviewed</b>	0
<b>Number of applications for SSA review over 14 days</b>	0
<b>Number of applications for SSA review over 14 days as % of all Phase 1 (SSAs)</b>	0%
<b>Number of substantial amendments reviewed</b>	125
<b>Number of substantial amendments over 35 days</b>	6
<b>Number of substantial amendments over 35 days as a % of total substantial amendments</b>	4.80%
<b>Number of Section 30 applications reviewed</b>	0
<b>Number of Section 30 applications over 60 days</b>	0
<b>Number of Section 30 applications over 60 days as a % of total Section 30 applications</b>	0%
<b>Number of modified amendments reviewed</b>	2
<b>Number of modified amendments over 14 days</b>	0
<b>Number of modified amendments over 14 days as a % of total modified amendments</b>	0.0%
<b>Number of proportionate review applications for ethical review over 14 days*</b>	3
<b>Number of proportionate review applications over 14 days as a % of total</b>	37.50%

**Table 8: Breakdown of current status of all applications reviewed within the reporting period:**

<b>Further Information Favourable Opinion with Standard Conditions</b>		
<b>REC Reference</b>	<b>Application Short Title</b>	<b>Number of Days on Clock</b>
12/EE/0163	Living with breathlessness (version 1)	56
12/EE/0172	A study of common and rare genetic variants associated with thinness.	50
12/EE/0176	ML28096-Tapered vs stable dose with RoActemra and methotrexate in RA	31
12/EE/0189	Reward prediction error in health and disease (version 1.0).	55
12/EE/0190	Effects of frontal, temporal and parietal lesions on memory	56
12/EE/0226	T2DM, Obesity, IL-18, Monoclonal antibody (mAb), Efficacy	51
12/EE/0230	RITAZAREM: Rituximab vasculitis maintenance study	37
12/EE/0243	A diary study of intrusive memories in older adults V1.1	54
12/EE/0247	Evaluating the Whole Life Manual for Therapy	47
12/EE/0251	Feasibility study of the effectiveness and cost effectiveness of MODs	35
12/EE/0260	Gaucher Outcomes Survey [GOS] version 2, 26 September 2011.	38
12/EE/0271	SIOP CNS GCT II	51
12/EE/0272	Addressing social anxiety in adults who stutter V1	37
12/EE/0285	Attitudes towards the management of Neisseria gonorrhoeae version 1.0	13
12/EE/0299	How dispositional types affect help-seeking in adolescents	44
12/EE/0305	Cortical Reorganisation in CRPS-An EEG Study (Version No.1)	38
12/EE/0329	SafeBooSC:Safeguarding the brain of our smallest children	27
12/EE/0374	FREEDOM Study	63
12/EE/0405	Investigation of Segmental Overgrowth Disorders	36
12/EE/0416	Can PET-CT predict genotype & pathology in Conn's adenomas?	49
12/EE/0419	Study of the Aetiology of Intestinal Failure associated Liver Disease	52
12/EE/0426	Protracted survival following withdrawal of neonatal intensive care	56
12/EE/0429	Expressed Emotion and Attributions in Paid Dementia Care Staff	21
12/EE/0431	Oral anticoagulant agent associated bleeding events reporting system	16
12/EE/0458	Parents and Young Children under Extreme Stress (PYCES)	36
12/EE/0467	Immuno-phenotyping schizophrenia	39
12/EE/0473	DREAM TAVI study	43
12/EE/0477	The Hyperglycemia and Pregnancy Outcome (HAPO) Follow-Up Study	41

12/EE/0480	Non invasive cardiac output monitoring - a validation study	60
12/EE/0481	Dapagliflozin vs Placebo plus Saxagliptin & Metformin in T2DM	37
12/EE/0489	IL-2 Single Photon Emission Tomography Imaging for Immunoinflammation	50
12/EE/0492	ARISE (Acid Lipase Replacement Investigating Safety and Efficacy)	50
12/EE/0515	Zoledronic Acid in Cystic Fibrosis	35
12/EE/0518	Information and the third stage of labour	19
13/EE/0015	Effect of A Reduction in GFR after Nephrectomy on Arterial Stiffness	49
13/EE/0016	National Diet and Nutrition Survey (NDNS) Rolling Programme Y6-9	60
13/EE/0023	ASP1707 in Subjects with Endometriosis Associated Pelvic Pain	34
13/EE/0027	Impact of broccoli-derived bioactives on tissues of the joint	58

<b>Further Information Favourable Opinion with Additional Conditions</b>		
<b>REC Reference</b>	<b>Application Short Title</b>	<b>Number of Days on Clock</b>
12/EE/0167	Functional results of conservatively treated Tendo Achilles ruptures	60
12/EE/0376	Dopa-responsive dystonia study	43
12/EE/0411	Eating disturbances in adolescents with chronic illness.	42
12/EE/0422	Infections with fimbriated bacteria and ANCA-associated vasculitis	49

<b>Further Information Unfavourable Opinion</b>		
<b>REC Reference</b>	<b>Application Short Title</b>	<b>Number of Days on Clock</b>

<b>Favourable Opinion with Standard Conditions</b>		
<b>REC Reference</b>	<b>Application Short Title</b>	<b>Number of Days on Clock</b>
12/EE/0282	Prescribing a programme to maximise speech perception (version 2)	7
12/EE/0430	UKOSS: Epidural Haematoma and Abscess	8
12/EE/0517	Dataset extension for optimizing the DR screening interval	9

<b>Favourable Opinion with Additional Conditions</b>		
<b>REC Reference</b>	<b>Application Short Title</b>	<b>Number of Days on Clock</b>

12/EE/0331	ACtive Treatment for Idiopathic AdolescenT Scoliosis: pilot RCT (V1.0)	26
12/EE/0346	The EPIC-Norfolk Fourth Health Check (4HC)	27
12/EE/0371	Phase III Study Comparing Betrixiban with Enoxaparin in VTE	26
13/EE/0074	Dietary Lipid Delivery	54
13/EE/0078	Muscle and bone health in children	53

<b>Unfavourable Opinion</b>		
<b>REC Reference</b>	<b>Application Short Title</b>	<b>Number of Days on Clock</b>
12/EE/0283	Patient empathy	7
12/EE/0293	Prospective evaluation of MR-TRUS fusion template re-biopsy (Pro-FUSE)	34
12/EE/0365	A model to predict the pretest probability of PE in pregnant patients	26
12/EE/0512	Maternal mood in pregnancy and infant development.	33
13/EE/0089	Mavrilimumab versus Anti tumor Necrosis Factor in Rheumatoid Arthritis	32

<b>Provisional Opinion</b>		
<b>REC Reference</b>	<b>Application Short Title</b>	<b>Number of Days on Clock</b>
13/EE/0059	Maternal mood in pregnancy and infant development.	N/A
13/EE/0079	Repeat Teenage Abortion (ReTA) Study	N/A
13/EE/0099	A study in patients aged 12-75 with severe OCS-dependent asthma	N/A

<b>Provisional Opinion Pending Consultation with Referee</b>		
<b>REC Reference</b>	<b>Application Short Title</b>	<b>Number of Days on Clock</b>

<b>Further information response not complete</b>		
<b>REC Reference</b>	<b>Application Short Title</b>	<b>Number of Days on Clock</b>

<b>Withdrawn after the meeting</b>		
<b>REC Reference</b>	<b>Application Short Title</b>	<b>Number of Days on Clock</b>

<b>Invalid Application</b>		
<b>REC Reference</b>	<b>Application Short Title</b>	<b>Number of Days on Clock</b>

<b>No Opinion Pending Consultation with Referee</b>		
<b>REC Reference</b>	<b>Application Short Title</b>	<b>Number of Days on Clock</b>

<b>Not Requiring Review by NHS REC</b>		
<b>REC Reference</b>	<b>Application Short Title</b>	<b>Number of Days on Clock</b>

**Table 9: Items exceeding timelines:**

<b>Full applications for ethical review over 60 day timeline</b>		
<b>REC Reference</b>	<b>Application Short Title</b>	<b>Number of Days on Clock</b>
12/EE/0374	FREEDOM Study	63

  

<b>Proportionate review applications for ethical review over 14 days timeline</b>		
<b>REC Reference</b>	<b>Application Short Title</b>	<b>Number of Days on Clock</b>
12/EE/0429	Expressed Emotion and Attributions in Paid Dementia Care Staff	21
12/EE/0431	Oral anticoagulant agent associated bleeding events reporting system	16
12/EE/0518	Information and the third stage of labour	19

  

<b>SSAs (non Phase 1) over 25 days timeline</b>		
<b>REC Reference</b>	<b>Application Short Title</b>	<b>Number of Days on Clock</b>
12/EE/0296	BDNF gene neuroplasticity study	38
12/EE/0297	'LARK2' Neurocognition Study	41

  

<b>SSAs (Phase 1) over 14 days timeline</b>		
<b>REC Reference</b>	<b>Application Short Title</b>	<b>Number of Days on Clock</b>

  

<b>Substantial Amendments over 35 day timeline</b>			
<b>Amendment Reference</b>	<b>Application Short Title</b>	<b>Amendment Title</b>	<b>Number of Days on Clock</b>
09/H0305/79/AM10	Protocol F1J-US-HMGO Neurobiology of Major Depressive Disorder	Amendment # 10	36
12/EE/0036/AM01	Study to Evaluate the Efficacy &	Amendment 2_Submission of	36

	Safety of LY2439821 Vs Placebo in Ps	Additional Documents _17	
97/5/007/AM30	UKFOCSS UK Familial Ovarian Cancer Screening Study	Substantial Amendment #23	39
09/H0305/79/AM14	Protocol F1J-US-HMGO Neurobiology of Major Depressive Disorder	Substantial Amendment #14	39
12/EE/0036/AM06	Study to Evaluate the Efficacy & Safety of LY2439821 Vs Placebo in Ps	Substantial Amendment Annex 2	45
12/EE/0089/AM01	The Efficacy & Safety of LY2439821, Etanercept Vs Placebo in Ps	Substantial Amendment Annex 2	45

#### **Modified Amendments over 14 day timeline**

<b>Amendment Reference</b>	<b>Application Short Title</b>	<b>Amendment Title</b>	<b>Number of Days on Clock</b>
----------------------------	--------------------------------	------------------------	--------------------------------

#### **Section 30 application over 60 day timeline**

<b>Amendment Reference</b>	<b>Application Short Title</b>	<b>Amendment Title</b>	<b>Number of Days on Clock</b>
----------------------------	--------------------------------	------------------------	--------------------------------